- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of June 11
The Center for Biosimilars® recaps the top 5 articles for the week of June 11, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 11.
Number 5: HHS Secretary Alex Azar testified before the Senate Committee on Health, Education, Labor, and Pensions on the Trump administration’s blueprint to lower drug prices, but The American College of Rheumatology is raising concerns about some of HHS’s proposals.
Number 4: The FDA has announced the publication of 2 final guidance documents that seek to provide greater clarity on medical product communications.
Number 3: Research presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, in Amsterdam, Netherlands, finds that, once patients are educated about biosimilars, most are willing to switch.
Number 2: The Senate Judiciary Committee voted 16 to 5 to report the CREATES Act to the Senate floor.
Number 1: Walgreen and Kroger have filed an antitrust suit against Johnson & Johnson and Janssen, alleging unlawful exclusion of biosimilar competition for infliximab.
Finally, last week, our e-newsletter asked whether the FDA’s approval of Fulphila will improve patient access to prophylaxis of febrile neutropenia.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
